menopause, not so fast
As an extension of platelet-rich plasma (PRP) efforts initially described in Greece, FertiGen is a minimally invasive method to insert the patient’s own platelet-derived growth factors precisely into ovarian tissue, near potential eggs.
To explore and refine this, Dr. Sills gained notoriety as Principal Investigator for the world’s first study of “ovarian rejuvenation”, as registered with ClinicalTrials.gov.
Since then, women from many nations have sought Team Sills for our unrivaled experience. Hundreds of procedures have been completed here giving an impressive overall patient satisfaction rate, with no complications.
What’s the source of this renewal? Let’s give proper credit .. to your own healthier ovarian tissue!
As discussed in Ovarian Reboot—Dr. Sills’ most recent book—the ovary is surrounded by a surface layer of cells undergoing rupture and repair with every ovulation.
This basic process is often regarded as trivial at some IVF clinics. But here, we consider this critically essential as the monthly process of ovulation itself causes unrelenting stress on the ovary — until of course menopause stops everything.
While stem cells are presumed to organize regeneration and repair events after this monthly “microtrauma”, it’s controversial and the mode of action for this remains incompletely characterized.
Although a few labs have advanced the understanding of ovarian stem cell biology, clinical applications are still being developed. The work by Dr. Sills at CAG is generating original data on this important topic.
This is where platelets become relevant. Use of PRP is perhaps best known as a remedy for low platelets to improve overall blood function. But PRP also emits soluble mediators which orchestrate many immune responses and tissue regeneration.
Closely associated with inflammation and its many mediators, PRP figures prominently in wound repair and directs a complex regulatory interplay of cellular migration, extracellular matrix remodeling, cell proliferation, apoptosis, differentiation, and angiogenesis.
In other words, signal transmissions from FertiGen are known to influence neighboring cells. Notwithstanding the now well-established surgical role of PRP in wound healing and tissue repair, clinical data have suggested that platelets can contribute to overall organ function as well.
Hardly a year passes without drug-makers announcing some new HRT method like shots, pills, patches, creams, or bedtime vaginal capsules placed just before sex. Yet, aren’t they all just clumsy, synthetic attempts to remedy an ovarian output diminished by age?
Even for someone not interested in regaining ovarian capacity specifically for personal fertility goals, a “reboot” to regain better & younger ovarian performance – naturally – still has value.
Because the central reason for so many IVF failures worldwide is linked to “old eggs” and the presumably unstoppable decline in ovarian function, the concept of FertiGen has emerged to confront both issues.
As the idea of lost reserve inexorably linked to ovarian failure is being challenged by current research, the possibility of changing the ovarian microenvironment—and even interacting with putative ovarian germline stem cells (GSC)—warrants consideration. This is where FertiGen steps on stage.